Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
Business Wire•03/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.